Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.54 |
| ▸ | TMEM97 | Q5BJF2 | 8/20 | 0.54 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16293030 | 0.89 | TMEM97 (0.56) | SIGMAR1TMEM97KDM5BSIRT2APP | |
| SCHEMBL16293406 | 0.88 | TMEM97 (0.54) | SIGMAR1TMEM97KDM5BSIRT2APP | |
| SCHEMBL16292674 | 0.86 | SIGMAR1 (0.53) | SIGMAR1TMEM97KDM5BSIRT2APP | |
| SCHEMBL18860206 | 0.78 | CHRM2 (0.42) | KDM5BSIRT2KDM4EALDH1A1 | |
| SCHEMBL16293073 | 0.77 | TMEM97 (0.45) | SIGMAR1TMEM97KDM5BSIRT2APP | |
| SCHEMBL16293072 | 0.77 | TMEM97 (0.45) | SIGMAR1TMEM97KDM5BSIRT2APP | |
| SCHEMBL16006932 | 0.77 | TMEM97 (0.45) | SIGMAR1TMEM97KDM5BSIRT2APP | |
| SCHEMBL18831147 | 0.75 | MC4R (0.44) | SIRT2KDM4E | |
| SCHEMBL18880300 | 0.75 | CHRM2 (0.42) | KDM5BSIRT2KDM4E | |
| SCHEMBL1268694 | 0.74 | SIGMAR1 (0.61) | SIGMAR1TMEM97APPACHEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2961736-B1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES INC (US) | 2018-04-11 | — | — | EP | claimed |
| EP-2961736-B1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES INC (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-2961736-B1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES INC (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-3170811-A1 | ETHYL PYRIDINE-4-CARBOXYLATE COMPOUND AS INHIBITOR OF HISTONE DEMETHYLASES | Gilead Sciences, Inc. (US) | 2017-05-24 | — | — | EP | disclosed |
| EP-3170811-A1 | ETHYL PYRIDINE-4-CARBOXYLATE COMPOUND AS INHIBITOR OF HISTONE DEMETHYLASES | Gilead Sciences, Inc. (US) | 2017-05-24 | — | — | EP | disclosed |
| US-9650339-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650339-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650339-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160237037-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160237037-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160237037-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| US-9221801-B2 | Inhibitors of histone demethylases | EPITHERAPEUTICS APS (DK) | 2015-12-29 | — | — | US | disclosed |
| US-9221801-B2 | Inhibitors of histone demethylases | EPITHERAPEUTICS APS (DK) | 2015-12-29 | — | — | US | disclosed |
| US-9221801-B2 | Inhibitors of histone demethylases | EPITHERAPEUTICS APS (DK) | 2015-12-29 | — | — | US | disclosed |
| US-20140371214-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2014-12-18 | — | — | US | disclosed |
| US-20140371214-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2014-12-18 | — | — | US | disclosed |
| US-20140371214-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2014-12-18 | — | — | US | disclosed |
| WO-2014131777-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EPITHERAPEUTICS APS (DK) | 2014-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371214-A1 | INHIBITORS OF HISTONE DEMETHYLASES | KDM1B, KDM1A, KDM3A | SIGMAR1 2943/4885TMEM97 3238/4885KDM5B 27/4885 |
| US-20160237037-A1 | INHIBITORS OF HISTONE DEMETHYLASES | KDM1B, KDM1A, KDM3A | SIGMAR1 2943/4885TMEM97 3238/4885KDM5B 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.